Compare Enact Holdings Inc (ACT) vs Novartis AG (NVS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Enact Holdings Inc vs Novartis AG — how do they compare? Enact Holdings Inc trades at $45.22 (market cap $6.35B), while Novartis AG trades at $155.52 (market cap $298.98B). The key difference: Novartis AG is far larger — about 47.1× Enact Holdings Inc's market cap, and Novartis AG pays the higher dividend (3.02%). Which is the better fit depends on your goals.
| ACT | NVS | |
|---|---|---|
Market Cap | $6.35B | $298.98B |
Sector | Technology | Health |
52-Week High | $45.71 | $168.62 |
52-Week Low | $34.39 | $113.50 |
Enterprise Value | $6.55B | $339.00B |
Dividend Yield | 1.91% | 3.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACT trades at $45.69, up 0.77% today, with a bullish technical signal and strong moving averages. The stock shows robust fundamentals with a net income margin of 54.49% and a P/E ratio of 9.89. Recent news includes a 14% dividend increase announced on May 5, 2026, and Q1 2026 earnings that met expectations. Analyst consensus is a $47.50 price target with a mix of buy and hold ratings.
Outlook remains positive due to high profitability and dividend growth, but risks include earnings volatility and market sensitivity. Upside is supported by institutional sentiment and consistent cash flow, though investors should monitor execution against future earnings estimates.
Novartis (NVS) trades at $157.03, down 1.79% with mixed technical signals showing bullish moving averages but neutral oscillators. The company demonstrates strong fundamentals with $56.67B revenue, 23.92% net margin, and robust cash flow generation. Recent developments include multiple strategic acquisitions and regulatory approvals expanding the oncology pipeline, though earnings have shown volatility with two misses in the last four quarters.
NVS presents a balanced investment case with strong profitability and pipeline expansion offset by valuation concerns and earnings inconsistency. The stock offers stability through defensive healthcare exposure but faces execution risks from integration challenges and competitive pressures in pharmaceutical markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enact Holdings Inc
Enact Holdings is a leading private mortgage insurance provider in the U.S. It partners with lenders to offer credit enhancement and risk management solutions, helping more borrowers achieve and maintain homeownership.
Read more on ACT →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
